Drug Type Peptide Conjugate Radionuclide, Cyclic Peptide, Therapeutic radiopharmaceuticals |
Synonyms 225AC-DOTATATE, [225Ac]Ac-DOTATATE, ACTINIUM AC 225 DOTATATE + [6] |
Target |
Action agonists |
Mechanism SSTR2 agonists(Somatostatin receptor 2 agonists) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Carcinoid Tumor | Phase 3 | United States | 24 Mar 2022 | |
| Carcinoid Tumor | Phase 3 | Belgium | 24 Mar 2022 | |
| Carcinoid Tumor | Phase 3 | Brazil | 24 Mar 2022 | |
| Carcinoid Tumor | Phase 3 | Canada | 24 Mar 2022 | |
| Carcinoid Tumor | Phase 3 | France | 24 Mar 2022 | |
| Carcinoid Tumor | Phase 3 | Netherlands | 24 Mar 2022 | |
| Carcinoid Tumor | Phase 3 | South Korea | 24 Mar 2022 | |
| Carcinoid Tumor | Phase 3 | Spain | 24 Mar 2022 | |
| Functioning Endocrine Neoplasm | Phase 3 | United States | 24 Mar 2022 | |
| Functioning Endocrine Neoplasm | Phase 3 | Belgium | 24 Mar 2022 |
Phase 1/2 | 15 | (177Lu-PRRT-treated) | mxmtfcoypj(scdfnemhrt) = Most common TRAEs included hypertriglyceridemia (61.9%), leukopenia (52.4%), and elevated ALT (47.6%) and most were G1-2 severity. Only one Grade 3 TRAE was reported, which was hypertriglyceridemia. No TRAE led to dose interruption, discontinuation or death. foaexhwqgn (ezejxshkcd ) View more | Positive | 23 Oct 2026 | ||
Phase 1 | 17 | hpibwphsrk(ibrlmwnxsr) = There was one grade 5 TEAE of hepatic failure that was deemed unrelated to the study drug rvwbqmhvph (sdanwvjcyr ) View more | Positive | 23 Jan 2025 | |||
NCT05595460 (WCLC2024) Manual | Phase 1 | 10 | qwpxmlkwmo(whzubsiwkc) = G1 decreased appetite, G2 dehydration, G1 diarrhea, G1 fatigue, G2 influenza-like illness, G2 nausea, G2 neutrophil count decrease, G1 vomiting xdglnehpiv (xzaelpbpbe ) View more | Positive | 08 Sep 2024 | ||
Phase 3 | - | RYZ101 120 kBq/kg | hekhlwelwn(vzgqmcrond) = 52.9% pzuubautgv (dieutolagn ) View more | - | 09 Jun 2024 | ||
Phase 1 | 17 | RYZ101 120 kBq/kg | zfocosuafw(dugibrnjcg) = wxxtckptxs wveuwsvtxt (gxbahpohto ) View more | Positive | 24 May 2024 | ||
Phase 1 | Gastro-Enteropancreatic Neuroendocrine Tumor SSTR positive | 17 | rhfuxhpvjr(zfrzrtdpps) = gpoyupnutr ivgmtillwl (bgewpkrceg ) View more | Positive | 22 Oct 2023 | ||
Phase 1 | SSTR2 positive Gastro-Enteropancreatic Neuroendocrine Tumor SSTR2 Expression | 9 | vjwsloksbd(jcduyxibro) = ciwszjdcww ubvnahcyji (yhcgaabnjv ) View more | Positive | 31 May 2023 | ||
Not Applicable | - | hpqgwqvckq(pqkovmjfio) = Malignant ascites was noted in 14, resulting in 11 deaths qyormcgdmi (ujblxpwoyd ) View more | - | 08 Aug 2022 | |||
Not Applicable | - | agxwodzoaf(kgipjwmknp) = No grade 3 renal or hepatotoxicities were observed. No other unexpected longer-term adverse events were observed with 225Ac-DOTATATE therapy rpaklkochh (zjyjmznnwh ) View more | - | 18 May 2021 |





